Glaucoma Therapeutics
1. Lumigan patent expiration
Treatment: Lumigan is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocula...
LUMIGAN's oppositions filed in EPO
LUMIGAN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7851504 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Jun, 2027
(1 year, 5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5688819 | ABBVIE | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Aug, 2014
(11 years ago) | |
| US6403649 | ABBVIE | Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Sep, 2012
(13 years ago) | |
| US8017655 | ABBVIE | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Nov, 2012
(13 years ago) | |
| US9155716 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8299118 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US9241918 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8309605 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8338479 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8524777 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8586630 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8278353 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8933127 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8933120 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| US8772338 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 31, 2013 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 16 March, 2001
Dosage: SOLUTION/DROPS
How can I launch a generic of LUMIGAN before it's drug patent expiration?
More Information on Dosage
LUMIGAN family patents
2. Omlonti patent expiration
Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10774072 | OCUVEX THERAP | Crystal of N-substituted sulfonamide compound |
Jun, 2035
(9 years from now) | |
| US8648097 | OCUVEX THERAP | Pyridylaminoacetic acid compound |
Oct, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12295946 | OCUVEX THERAP | NA |
Jan, 2035
(9 years from now) | |
| US12290511 | OCUVEX THERAP | NA |
Dec, 2038
(12 years from now) | |
| US11666563 | OCUVEX THERAP | Pharmaceutical preparation containing pyridyl aminoacetic acid compound |
Jul, 2039
(13 years from now) | |
| US11197849 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US10702511 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US10179127 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US9415038 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| USRE48183 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US11793798 | OCUVEX THERAP | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US10765750 | OCUVEX THERAP | Pharmaceutical composition containing pyridylaminoacetic acid compound |
Jan, 2035
(9 years from now) | |
| US8685986 | OCUVEX THERAP | Medical composition for treatment or prophylaxis of glaucoma |
Oct, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 22, 2027 |
Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient
NCE-1 date: 22 September, 2026
Market Authorisation Date: 22 September, 2022
Dosage: SOLUTION
More Information on Dosage
OMLONTI family patents
3. Rhopressa patent
expiration
Treatment: Reduction of elevated intraocular pressure
RHOPRESSA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8450344 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(5 months from now) | |
| US9096569 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(5 months from now) | |
| US10174017 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(4 years from now) | |
| US8394826 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Nov, 2030
(4 years from now) | |
| US9931336 | ALCON LABS INC | Combination therapy |
Mar, 2034
(8 years from now) | |
| US10654844 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(4 years from now) | |
| US10588901 | ALCON LABS INC | Combination therapy |
Mar, 2034
(8 years from now) | |
| US9415043 | ALCON LABS INC | Combination therapy |
Mar, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10882840 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(5 months from now) | |
| US10532993 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(5 months from now) | |
| US11618748 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(4 years from now) | |
| US11020385 | ALCON LABS INC | Combination therapy |
Mar, 2034
(8 years from now) | |
| US11021456 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(5 months from now) | |
| US11028081 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(4 years from now) | |
| US11185538 | ALCON LABS INC | Compositions for treating glaucoma or reducing intraocular pressure |
Mar, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2022 |
Drugs and Companies using NETARSUDIL MESYLATE ingredient
NCE-1 date: 18 December, 2021
Market Authorisation Date: 18 December, 2017
Dosage: SOLUTION/DROPS
How can I launch a generic of RHOPRESSA before it's drug patent expiration?
More Information on Dosage
RHOPRESSA family patents
4. Travatan patent expiration
Treatment: Method of stabilizing prostaglandin; Method for treating glaucoma and ocular hypertension
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5631287 | ALCON PHARMS LTD | Storage-stable prostaglandin compositions |
Dec, 2014
(11 years ago) | |
| US6011062 | ALCON PHARMS LTD | Storage-stable prostaglandin compositions |
Dec, 2014
(11 years ago) | |
| US5510383 | ALCON PHARMS LTD | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
Aug, 2013
(12 years ago) | |
| US5889052 | ALCON PHARMS LTD | Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension |
Dec, 2014
(11 years ago) | |
| US5849792 | ALCON PHARMS LTD | Storage-stable prostaglandin compositions |
Dec, 2014
(11 years ago) | |
Drugs and Companies using TRAVOPROST ingredient
Market Authorisation Date: 16 March, 2001
Dosage: SOLUTION/DROPS
How can I launch a generic of TRAVATAN before it's drug patent expiration?
More Information on Dosage
TRAVATAN family patents
5. Vizz patent expiration
Treatment: Treatment of presbyopia
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12414942 | LENZ THERAP | NA |
Mar, 2044
(18 years from now) | |
| US10052313 | LENZ THERAP | NA |
Mar, 2034
(8 years from now) | |
| US9844537 | LENZ THERAP | NA |
Mar, 2034
(8 years from now) | |
| US12128036 | LENZ THERAP | NA |
Oct, 2039
(13 years from now) | |
| US11179328 | LENZ THERAP | NA |
Mar, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2030 |
Drugs and Companies using ACECLIDINE HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2029
Market Authorisation Date: 31 July, 2025
Dosage: SOLUTION/DROPS
More Information on Dosage
VIZZ family patents
6. Vyzulta patent expiration
Treatment: Reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension
VYZULTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6211233 | BAUSCH AND LOMB | Prostaglandin pharmaceutical compositions |
Jun, 2018
(7 years ago) | |
| US8058467 | BAUSCH AND LOMB | Prostaglandin derivatives |
Feb, 2029
(3 years from now) | |
| US7910767 | BAUSCH AND LOMB | Prostaglandin derivatives |
Jan, 2025
(1 year, 4 days ago) | |
| US7273946 | BAUSCH AND LOMB | Prostaglandin derivatives |
Oct, 2025
(3 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7629345 | BAUSCH AND LOMB | Prostaglandin derivatives |
Jan, 2025
(1 year, 4 days ago) | |
Drugs and Companies using LATANOPROSTENE BUNOD ingredient
Market Authorisation Date: 02 November, 2017
Dosage: SOLUTION/DROPS
How can I launch a generic of VYZULTA before it's drug patent expiration?
More Information on Dosage
VYZULTA family patents
7. Zioptan patent expiration
Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension
ZIOPTAN's oppositions filed in EPO
ZIOPTAN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5886035 | THEA PHARMA | Difluoroprostaglandin derivatives and their use |
Dec, 2017
(8 years ago) | |
| US10864159 | THEA PHARMA | Method and composition for treating ocular hypertension and glaucoma |
May, 2029
(3 years from now) | |
| US9999593 | THEA PHARMA | Method and composition for treating ocular hypertension and glaucoma |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 10, 2017 |
Drugs and Companies using TAFLUPROST ingredient
NCE-1 date: 11 February, 2016
Market Authorisation Date: 10 February, 2012
Dosage: SOLUTION/DROPS
How can I launch a generic of ZIOPTAN before it's drug patent expiration?
More Information on Dosage
ZIOPTAN family patents